Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus XELOX versus placebo plus XELOX as first-line treatment for unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma
CTR20211567Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Sep 2021; status: completed.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20211567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211567.